NICE climbdown over anti-flu drug Relenza

Posted on September 1st, by editor in Caring Times. No Comments

Elderly people in care homes are among those who will benefit from a change of heart by the National Institute of Clinical Excellence (NICE) with regard to the anti-flu drug Relenza. NICE reversed a decision last year not to make the drug available on the NHS, and now says that people over 65, those with respiratory disease, those with lowered resistance to infection (for example, those with diabetes) should have access to the drug when flu is “circulating in the community”. Official guidelines suggest that this occurs when 50 to 400 cases of flue occur per 100,000 GP consultations. Vaccination remains the mainstay of preventing flu in all those at risk, but Relenza will, in some patients, reduce the chances of developing flu, and may reduce the length and severity of the illness.

Comments are closed.

Latest blog posts

Shuffling to some purpose – or just fancy footwork?

By guest blogger JEF SMITH

Spare a thought if you will for the hard pressed people who have to update government information. Well into 2018, for...

Life support for the NHS

By Caring Times editor GEOFF HODGSON

To outline a comprehensive remedy for the ongoing and worsening woes of the beleaguered NHS would take a little more...

A flight of festive fancy

By Caring Times editor GEOFF HODGSON

Christmas Past: It’s cold outside but inside the care home the star atop the tree beams its rays of hope...